Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mesenchymal stem cell-derived exosomes: Regulators of progression and suppression in pancreatic cancer (Review)

Zhuang H., Shi X.

Narrative Review on Immune Modulation, published in Oncol Lett (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Oncol Lett (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41230101
PMCID
PMC12603484
DOI
10.3892/ol.2025.15374

Abstract (original English)

Pancreatic cancer is a malignant digestive tract tumor with a poor prognosis. It remains one of the most challenging malignancies due to difficulties in early diagnosis and the development of chemotherapy resistance in advanced stages. Mesenchymal stem cells (MSCs), a distinct type of non-hematopoietic stem cells, play a crucial role in the tumor microenvironment owing to their unique tumor-homing capacity and immunomodulatory properties, which are largely mediated by their derived exosomes (EXOs). EXOs derived from MSCs can regulate the growth, invasion and metastasis of pancreatic cancer through the activation of specific signaling pathways. Furthermore, they have emerged as promising drug delivery vehicles and have demonstrated potential in anti-pancreatic cancer therapy. However, within the highly fibrotic tumor microenvironment of pancreatic cancer, the functions of MSC-derived EXOs are complex and dualistic, exhibiting both tumor-suppressive and tumor-promoting effects. Understanding the precise roles of MSC-derived EXOs in pancreatic cancer is essential for the development of effective therapeutic strategies. The present review systematically summarizes the dual regulatory mechanisms of MSC-derived EXOs in pancreatic cancer, elucidates the key molecules and signaling pathways involved, and discusses their clinical potential as novel therapeutic targets or drug delivery s

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research